New anti-T cell immunotoxins for the clinic

Leukemia Research

Volumn 29, Issue 3, 2005, Pages 249-251

  Frankel, Arthur E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENILEUKIN DIFTITOX; IMMUNOTOXIN; IMMUNOTOXIN LMB2; SARCOSINE;

CANCER IMMUNOTHERAPY; CELL TRANSPLANTATION; DNA MODIFICATION; DRUG CYTOTOXICITY; DRUG RESEARCH; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOTOXINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 12344269809     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.08.011     Document Type: Editorial

References (21)

1. A.E. Frankel, R.J. Kreitman, I. Pastan, and J.R. Murphy Immunotoxins R.K. Oldham Principles of cancer biotherapy 4th revised ed. 2003 391
2. 389IL2 (ONTAK) for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 2001 376
3. Dang NH, Pro B, Hagemeister FB, Jones D, Samuels B, Rodriguez MA, et al. Interim analysis of a phase II study of denileukin diftitox (ONTAK) for relapsed/refractory T-cell non-Hodgkin's lymphoma. Blood, in press.
4. V.T. Ho, D. Zahrieh, E. Hochberg, E. Micale, J. Levin, and C. Reynolds Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Blood 104 2004 1224
5. R.J. Kreitman, W.H. Wilson, J.D. White, M. Stetler-Stevenson, E.S. Jaffe, and S. Giardina Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies J Clin Oncol 18 2000 1622
6. R. Schnell, P. Borchmann, J.O. Staak, J. Schindler, V. Ghetie, and E.S. Vitetta Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma Ann Oncol 14 2003 729
7. P.J. Martin, J. Pei, T. Gooley, C. Anasetti, F.R. Appelbaum, and J. Deeg Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation Biol Blood Marrow Transplant 10 2004 552
8. T.A. Waldmann, I. Pastan, O. Gansow, and R.P. Junghans The multichain interleukin-2 receptor: a target for immunotherapy Ann Int Med 116 1992 148
9. A.E. Frankel, J.H. Laver, M.C. Willingham, L.J. Burns, J.H. Kersey, and D.A. Vallera Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin Leuk Lymphoma 26 1997 287
10. C.F. LeMaistre, S. Rosen, A.E. Frankel, S. Kornfeld, E. Saria, and C. Meneghetti Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma Blood 78 1991 1173
11. P.J. Martin, B.J. Nelson, F.R. Appelbaum, C. Anasetti, H.J. Deeg, and J.A. Hansen Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation Blood 88 1996 824
12. Y.V. van Oosterhout, L. van Emst, A.V. Schattenberg, W.J. Tax, D.J. Ruiter, and H. Spits A combination of anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease Blood 95 2000 3693
13. D.A. Vallera, R.C. Ash, E.D. Zanjani, J.H. Kersey, T.W. LeBien, and P.C. Beverley Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies Science 222 1983 512
14. R.J. Youle, F.M. Uckun, D.A. Vallera, and M. Colombatti Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen J Immunol 136 1986 93
15. J.M. Hexham, D. Dudas, R. Hugo, J. Thompson, V. King, and C. Dowling Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins Mol Immunol 38 2001 397
16. D.A. Vallera, D. Todhunter, D.A. Kuroki, Y. Shu, A. Sicheneder, and A. Panoskaltsis-Mortari Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice Leuk Res 29 2005 331 341
17. D.A. Vallera, A. Panoskaltsis-Mortari, C. Jost, S. Ramakrishnan, C.R. Eide, and R.J. Kreitman Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immuno-toxin specifically targeting the CD3 epsilon moiety of the T-cell receptor Blood 88 1996 2342
18. D.A. Vallera, A. Panoskaltsis-Mortari, and B.R. Blazar Renal dysfunction accounts for the dose limiting toxicity of DT390anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin Protein Eng 10 1997 1071
19. D.A. Vallera, D.W. Kuroki, A. Panoskaltsis-Mortari, D.J. Buchsbaum, B.E. Rogers, and B.R. Blazar Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model Blood 96 2000 1157
20. J. Thompson, S. Stavrou, M. Weetall, J.M. Hexham, M.E. Digan, and Z. Wang Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion Protein Eng 14 2001 1035
21. J.H. Woo, Y.Y. Liu, S. Stavrou, and D.M. Neville Increased secretion of a bivalent anti-T cell immunotoxin by Pichia pastoris Appl Environ Microbiol 70 2004 3370